<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005757</url>
  </required_header>
  <id_info>
    <org_study_id>32RA13007</org_study_id>
    <nct_id>NCT02005757</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)</brief_title>
  <acronym>AMOLED</acronym>
  <official_title>Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and
      50mg tid in active rheumatoid arthritis patients unsuccessfully treated with
      disease-modifying antirheumatic drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. EULAR Response after 24weeks of treatment

        2. EULAR Response after 12weeks of treatment

        3. DAS28 value change

        4. KHAQ-20 value change
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Bredinin tablet 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage form: Tablet, dosage: 150mg qd, Duration: for 6months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bredinin tablet 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dosage form: Tablet, dosage: 50mg tid, Duration: for 6months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bredinin tablet 150mg</intervention_name>
    <description>Bredinin 150mg qd vs Bredinin 50mg tid</description>
    <arm_group_label>Bredinin tablet 150mg</arm_group_label>
    <other_name>Mizoribine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bredinin tablet 50mg</intervention_name>
    <description>Bredinin 150mg qd vs Bredinin 50mg tid</description>
    <arm_group_label>Bredinin tablet 50mg</arm_group_label>
    <other_name>Mizoribine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged from 20 to 80 years old

          -  Signed and dated informed consent document indicating that the patient

          -  Patients must have a diagnosis of Rheumatoid Arthritis(RA) of at least 3months
             duration as defined by the 2010 American College of Rheumatology(ACR) Classification
             criteria.

          -  Patients should have a Disease Activity Score 28 greater than or equal to 3.2 (DAS28 ≥
             3.2) and have received treatment with more than 1 kind of disease-modifying
             antirheumatic drug(including MTX).

          -  ESR≥28mm/h or CRP≥1.0mg/dl at screening.

        Exclusion Criteria

          -  At screening, patients have laboratory result as defined by : white blood cell ≤
             3,000/mm3

             , Hemoglobin &lt; 8.5 g/dL, Platelet count &lt; 100,000/mm3, Serum creatinine &gt; 2.0 mg/dL,
             Aspartic Acid Transaminase/Alanine Transaminase ≥ 2*upper limit of normal , Uric acid
             ≥ 1.5*upper limit of normal

          -  Patient must not have bleeding disorder or taking anticoagulant. (But, lt is allowed
             to take 100mg/day of Asprin)

          -  Patients with a history of operation on index knee joint which could have influence on
             the result and need to have surgery as determined by investigator.

          -  Patients have severe infection, including moderate respiratory disease and have
             received treatment with systemic antibiotics within 2 weeks.

          -  Patients have cardiovascular disease or associated disease which is not controlled.

          -  Patients have a history of malignancy within 5years. (But, basal cell or squamous cell
             carcinoma or carcinoma in situ of the uterine cervix have been treated is allowed)

          -  Patients have hypersensitivity reaction on this drug.

          -  Patients on any other clinical trial or experimental treatment in the past 3months.

          -  Female patients who are breast feeding, pregnant or plan to become pregnant during the
             trial or for two months following study termination.

          -  Not allowable medication recorded below ; Intra-articular injections within weeks at
             baseline visit, Patients taking oral steroid over 10mg /day or using new treatment or
             changing dosage within 4weeks at baseline visit, Using new nonsteroidal
             antiinflammatory drug within 4 weeks or changing nonsteroidal antiinflammatory drug
             dosage within 2 weeks at baseline visit.

          -  Having experience of use biologic agent, immunosuppressant, cytostatic preparations
             within 8weeks at baseline visit. (But, Rituximab is not allowed within 6months)

          -  Start to treatment new disease-modifying antirheumatic drug or need to change dosage
             of disease-modifying antirheumatic drug which is taking on the trial.
             (Leflunomide(ARAVA®) is not allowed within 12weeks, But, Cholestyramine is allowed
             after 48 hours later stopping. if it use three times a day, 8g, for 11days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Su Kim, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Gangneng asan Medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Su Kim, M.D., Ph.D</last_name>
    <phone>82-33-610-3126</phone>
    <email>DrKiss@korea.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Il Seo, PhD</last_name>
      <email>yiseo@hallym.or.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Il Seo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyeong Min Son, PhD</last_name>
      <email>jollyfox@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyeong Min Son</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donghyuk Sheen, PhD</last_name>
      <email>rheuma@eulji.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Donghyuk Sheen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Soo Kim, Ph.D</last_name>
      <phone>82-33-610-3061</phone>
      <email>drkiss@ulsan.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sung-Soo Kim, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Kangwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiwon Moon, PhD</last_name>
      <email>kiwonmoon@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kiwon Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Jae Hong, phD</last_name>
      <email>hsj718@khu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Jae Hong, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-sook Kim, PhD</last_name>
      <email>healthyra@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyunsook Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>Mizoribine</keyword>
  <keyword>DAS28</keyword>
  <keyword>European League Against Rheumatism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bredinin</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

